A systematic review of the evidence of clozapine's anti-aggressive effects

The International Journal of Neuropsychopharmacology
Catherine FrogleyMarco Picchioni

Abstract

Reducing the risk of violent and aggressive behaviour in patients with schizophrenia remains a clinical priority. There is emerging evidence to suggest that the second-generation antipsychotic, clozapine, is effective at reducing this risk in patients with schizophrenia and some evidence to suggest that it may be best in selected patients. We conducted a systematic literature search in March 2011 of all prospective and retrospective studies, which investigated clozapine's anti-aggressive effects in a variety of mental disorders. The review identified six animal studies, four randomized controlled trials, 12 prospective non-controlled studies and 22 retrospective studies, with four case studies. We found considerable evidence in support of clozapine's ability to reduce violent and aggressive behaviour. Clozapine's anti-aggressive effect was most commonly explored in patients with schizophrenia, with less evidence available for other psychiatric disorders, including borderline personality disorder, autistic spectrum disorders, post-traumatic stress disorder, bipolar disorder and learning disability. There was mixed evidence to address the question of whether or not clozapine was any more effective than other antipsychotics. In th...Continue Reading

References

Nov 1, 1992·Australian and New Zealand Journal of Ophthalmology·D StarkC Morrey
Jan 1, 1992·Physiology & Behavior·L GarmendiaV M Simón
Jan 24, 1989·European Journal of Pharmacology·B A McMillenM E Rodriguez
Sep 1, 1988·The Journal of Nervous and Mental Disease·S R KayL M Murrill
Sep 1, 1988·The Journal of Nervous and Mental Disease·J N HerreraB N Nguyen
Jan 1, 1986·The American Journal of Psychiatry·S C YudofskyD Williams
Aug 1, 1995·Journal of Consulting and Clinical Psychology·M Hillbrand
Apr 1, 1995·Psychiatric Services : a Journal of the American Psychiatric Association·W H Wilson, A M Claussen
Jul 1, 1994·The British Journal of Psychiatry : the Journal of Mental Science·J Smith, S Hucker
Nov 1, 1993·Comprehensive Psychiatry·F R Frankenburg, M C Zanarini
Jan 1, 1994·The American Journal of Psychiatry·A BreierW T Carpenter
Jun 1, 1993·Journal of Clinical Psychopharmacology·M L MichalsA Childs
Aug 1, 1993·Journal of Clinical Psychopharmacology·J VolavkaP Czobar
Jan 1, 1996·Psychiatric Services : a Journal of the American Psychiatric Association·A A MendittoL J Baldwin
Dec 15, 1996·Schizophrenia Research·J RabinowitzV Rosenberg
Nov 5, 1997·Epidemiology·A M WalkerK J Rothman
Jan 20, 1998·The American Journal of Psychiatry·M P Freeman, A L Stoll
Apr 16, 1998·The Journal of Clinical Psychiatry·F BenedettiE Smeraldi
Jun 5, 1998·The Harvard Mental Health Letter
Aug 26, 1998·Psychiatric Services : a Journal of the American Psychiatric Association·W H ReidT Hogan
Dec 19, 1998·Social Psychiatry and Psychiatric Epidemiology·B G LinkJ Phelan
Jan 16, 1999·Psychiatric Services : a Journal of the American Psychiatric Association·T SteinertR P Gebhardt
Jul 8, 1999·Biological Psychiatry·J P McEvoyW H Wilson
May 2, 2000·The British Journal of Psychiatry : the Journal of Mental Science·J MunroR Kerwin
Jun 1, 2000·Journal of Clinical Psychopharmacology·I ModaiM Ritsner
Jun 10, 2000·The Journal of Clinical Psychiatry·R RosenheckD Charney
Feb 7, 2001·The American Journal of Psychiatry·W FrankleD Henderson
Apr 3, 2001·The Journal of Hand Surgery·K A BarrieS W Wolfe
Jun 1, 2001·The American Journal of Psychiatry·M J SernyakR Rosenheck
Jul 7, 2001·Journal of Autism and Developmental Disorders·R HammockS R Schroeder
Oct 31, 2001·Psychiatric Services : a Journal of the American Psychiatric Association·L CitromeJ A Lieberman
Dec 1, 2001·Schizophrenia Research·K N R ChengappaN Schooler
Jan 31, 2002·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·L ChalasaniK N Chengappa
Mar 5, 2002·Psychiatric Services : a Journal of the American Psychiatric Association·George F Parker
Jun 4, 2002·The British Journal of Psychiatry : the Journal of Mental Science·Elizabeth WalshThomas Fahy

❮ Previous
Next ❯

Citations

Dec 12, 2012·The Psychiatric Quarterly·Vanessa BobbMark Olfson
Apr 9, 2014·BMC Psychiatry·Stephanie Warnez, Silvia Alessi-Severini
Aug 30, 2014·Journal of Psychiatric Research·Elizabeth D BallardCarlos A Zarate
Jan 16, 2016·Journal of Child and Adolescent Psychopharmacology·Ozhan YalcinOzden Sukran Uneri
Nov 22, 2012·International Journal of Mental Health Nursing·Geoffrey DickensNick Alderman
Sep 25, 2015·Journal of Child and Adolescent Psychopharmacology·Hatice GunesAyten Erdogan
Mar 31, 2015·CNS Spectrums·Laura J DardashtiGeorge J Proctor
Apr 6, 2012·The International Journal of Neuropsychopharmacology·Jan Volavka
Jan 28, 2017·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Alessandro RimessiPaolo Pinton
Dec 17, 2016·American Journal of Therapeutics·Petru IfteniAndreea Teodorescu
Mar 2, 2016·European Psychiatry : the Journal of the Association of European Psychiatrists·J RamplingS P Singh
Jul 14, 2017·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Gary RemingtonMichael Teehan
Dec 19, 2015·International Journal of Psychiatry in Medicine·Nitin Chopra, Jose de Leon
Aug 2, 2014·Therapeutic Advances in Psychopharmacology·Sarah Elizabeth Argent, Simon Alastair Hill
Aug 25, 2015·Therapeutic Advances in Psychopharmacology·Cana Aksoy PoyrazAlaattin Duran
Oct 11, 2016·Therapeutic Advances in Psychopharmacology·John KasinathanAnthony Barker
Sep 19, 2018·BJPsych Bulletin·Alex TillEdward Silva
Oct 5, 2018·Journal of Clinical Psychopharmacology·Maud RothärmelOlivier Guillin
Jan 29, 2019·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Myrthala Juárez-TreviñoRosalinda Sepúlveda Sepúlveda
Jan 30, 2015·European Journal of Clinical Pharmacology·Z WhitneyA M Barr
Apr 4, 2015·Journal of Clinical Psychopharmacology·Jimmy LeeGary Remington
Jan 22, 2018·European Psychiatry : the Journal of the Association of European Psychiatrists·Amelia JewellKimberlie Dean
Jan 30, 2020·The International Journal of Neuropsychopharmacology·E di GiacomoUNKNOWN VIORMED-2 Group
Jun 24, 2017·The Psychiatric Quarterly·Kathleen PatchanDeanna L Kelly
Jul 28, 2016·Clinical Schizophrenia & Related Psychoses·Leslie CitromeStephen R Saklad
Sep 1, 2015·Journal of Epidemiology and Community Health·Mohit VarshneyKoushik Sinha Deb
Apr 3, 2014·Early Intervention in Psychiatry·Gabrielle Crépeau-Gendron, Sophie L'heureux
Apr 24, 2018·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Alexander Panickacheril JohnArun Dominic

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.

Autism

Autism spectrum disorder is associated with challenges with social skills, repetitive behaviors, and often accompanied by sensory sensitivities and medical issues. Here is the latest research on autism.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.

Autism: Treatment Targets

The absence of effective treatments for autism are due to the high clinical and genetic heterogeneity between affected individuals, restricted knowledge of the underlying pathophysiological mechanisms, and the lack of reliable diagnostic biomarkers. Identification of more homogenous biological subgroups is therefore essential for the development of novel treatments based on the molecular mechanisms underpinning autism and autism spectrum disorders. Find the latest research on autism treatment targets here.